Sungwook Choi

Title: Innovations by Sungwook Choi

Introduction

Sungwook Choi is a notable inventor based in Yuseong-gu, Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of small molecules that interact with transthyretin, a crucial plasma protein.

Latest Patents

Sungwook Choi holds 2 patents related to small molecules that covalently modify transthyretin. His latest patents disclose a family of covalent kinetic stabilizer compounds that selectively and covalently react with transthyretin, demonstrating a preference over more than 4000 other human plasma proteins. The compounds are designed to react chemoselectively with specific amino groups within the transthyretin tetramer. The crystal structure of these compounds confirms their binding orientation and the conjugating amide bond. Notably, these covalent transthyretin kinetic stabilizers exhibit superior amyloid inhibition potency compared to non-covalent counterparts, effectively inhibiting cytotoxicity associated with amyloidogenesis.

Career Highlights

Sungwook Choi is affiliated with The Scripps Research Institute, where he continues to advance research in his field. His work has garnered attention for its potential applications in treating amyloid-related diseases.

Collaborations

One of his notable collaborators is Jeffery W. Kelly, with whom he has worked on various projects related to transthyretin and its implications in health.

Conclusion

Sungwook Choi's innovative work in developing covalent kinetic stabilizers for transthyretin represents a significant advancement in biochemistry. His contributions have the potential to impact the treatment of amyloid-related conditions, showcasing the importance of his research in the scientific community.